

**From:** Kelly, Sondag  
**To:** [Denloye, Aderonke O \(Ade\\_Denloye@baxter.com\)](mailto:Denloye.Aderonke.O@baxter.com)  
**Cc:** [Maruna, Thomas \(Thomas.Maruna@fda.hhs.gov\)](mailto:Maruna.Thomas@fda.hhs.gov)  
**Subject:** FDA Request for Info - Immune Globulin Subcutaneous (Human), 20% Solution - BL 125596/0  
**Date:** Wednesday, July 20, 2016 12:49:00 PM  
**Importance:** High

---

*Sent on behalf of LT Thomas Maruna*

Our Reference: BL 125596/0

Baxalta US, Inc.  
Attention: Ms. Aderonke Denloye  
July 20, 2016  
Sent by email

Dear Ms. Denloye:

We are reviewing your September 14, 2015 BLA for Immune Globulin Subcutaneous (Human), 20% Solution to treat primary immune deficiency disorders associated with defects in humoral immunity .

We determined that the following information is necessary to continue our review:

1. For the “Purity by (b) (4)” assay (CTP LE-13-A05001), you have demonstrated the specificity and precision in your validation report. Please provide accuracy, linearity, and range data to complete a full validation for this quantitative method.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file by to this file *ASAP* referencing the date of this request. Please let us know when you would be able to provide the final validation report.

The action due date for this file is September 13, 2016.

If you have any questions this week, please contact me.

Sincerely,  
***Sondag L. Kelly, MS, RAC, PMP***

Regulatory Project Manager  
U.S. Food & Drug Administration  
Center for Biologics Evaluation and Research  
Office of Blood Research and Review  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Voice# 240.402.8410  
Mobile# 240.507.8446  
Fax# 301.595.1128

**THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT**

IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.